Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Genentech Announces Alexander Hardy As Chief Executive Officer

January 24th, 2019

Genentech, a member of the Roche Group, today announced the appointment of Alexander Hardy to chief executive officer, effective March 1, 2019.

Hardy first joined Genentech in 2005, where he held several senior management positions, including leading patient access services and overseeing commercial operations for a range of therapeutic areas from HER2-positive cancer to influenza and neuroscience. In 2014, he became head of Asia Pacific for Roche Pharmaceuticals and is currently head of Global Product Strategy. Hardy succeeds Bill Anderson, who was recently appointed chief executive officer, Roche Pharmaceuticals.

“We’re delighted to welcome Alexander back to Genentech as chief executive officer,” said Anderson. “He brings significant global expertise in the delivery of breakthrough medicines and a deep connection to the company culture. I look forward to seeing Genentech’s scientific excellence, employee experience and dedication to patients thrive under his leadership.”